Published online before print February 9, 2007, doi: 10.1161/01.RES.0000260179.43672.fe
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Molecular Medicine |
Important Role of Erythropoietin Receptor to Promote VEGF Expression and Angiogenesis in Peripheral Ischemia in Mice
From the Departments of Cardiovascular Medicine (M.N., K.S., Y.F., Y.I., Y.K., H.S.) and Microbiology and Immunology (N.I., K.S.), Tohoku University Graduate School of Medicine, Sendai, Japan.
Correspondence to Yoshihiro Fukumoto, MD, PhD, Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1–1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. E-mail fukumoto{at}cardio.med.tohoku.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We have recently demonstrated that endogenous erythropoietin (Epo)/Epo receptor (EpoR) system plays an important protective role in hypoxia-induced pulmonary hypertension. However, it remains to be examined whether vascular EpoR system contributes to angiogenesis in response to ischemia. We examined angiogenesis in EpoR–/–-rescued mice that lack EpoR in most organs including cardiovascular system except erythroid-lineage cells. Two weeks after femoral artery ligation, blood flow recovery, activation of VEGF/VEGF receptor system, and mobilization of endothelial progenitor cells were all impaired in EpoR–/–-rescued mice as compared with wild-type (WT) mice. Bone marrow (BM) transplantation with WT-BM cells in EpoR–/–-rescued mice partially but significantly improved blood flow recovery after hindlimb ischemia. The extent of VEGF upregulation and the number of BM-derived cells in ischemic tissue were significantly less in EpoR–/–-rescued mice compared with WT mice even after BM reconstitution with WT-BM cells. Similarly, the recovery of blood flow was significantly impaired in recipient EpoR–/–-rescued mice that had been transplanted with WT-BM or EpoR–/–-rescued-BM as compared with recipient WT mice. Furthermore, the Matrigel implantation assay and aortic ring assay showed that microvessel growth in vitro was significantly reduced in EpoR–/–-rescued mice as compared with WT mice. These results indicate that vascular EpoR system also plays an important role in angiogenesis in response to hindlimb ischemia through upregulation of VEGF/VEGF receptor system, both directly by enhancing neovascularization and indirectly by recruiting endothelial progenitor cells and BM-derived proangiogenic cells.
Key Words: angiogenesis • ischemia • progenitor cells • VEGF • erythropoietin
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Prognosis of patients with severe peripheral artery disease (PAD) still remains poor when there is no indications of revascularization therapies such as bypass surgery or percutaneous transluminal angioplasty.1 Angiogenesis is a promising new therapeutic strategy for severe PAD, however, the effects of angiogenic therapies to improve ischemia are not durable or stable.2–4 Hypoxia inducible factor-1 (HIF-1) is one of the important factors to induce angiogenesis,5,6 which upregulates both erythropoietin (Epo) and VEGF.7,8 These angiogenic cytokines play an important role in recruitment of bone marrow (BM)-derived cells to ischemic tissue, enhancing endothelial cell proliferation and migration, synthesis of extracellular matrix and resultant angiogenesis.9–11
Epo is a hypoxia-induced hormone that exclusively stimulates proliferation and differentiation of erythroid progenitor cells and endothelial cells.12–15 Furthermore, systemic administration of Epo mobilizes endothelial progenitor cells (EPCs) and recruits them to ischemic tissue,16,17 where EPCs produce abundant cytokines including VEGF and promote postnatal vasculogenesis.18,19
Although Epo receptor (EpoR) is known to be expressed abundantly not only in BM but also in a variety of organs including cardiovascular system,20,21 the role of EpoR in ischemic tissue remains to be clarified. Suzuki et al have recently developed EpoR–/–-rescued mice that express EpoR only in the erythroid lineage but not in cardiovascular system21 and demonstrated the important protective role of endogenous Epo/EpoR system in hypoxia-induced pulmonary hypertension.21,22 However, it remains to be examined whether vascular Epo/EpoR system also plays an important role in ischemia-induced angiogenesis. In the present study, we thus addressed this important issue in EpoR–/–-rescued mice.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
All procedures were performed according to the protocols approved by the Institutional Committee for Use and Care of Laboratory Animals of Tohoku University.
Animal Preparation
In the present study, we used 12-week-old wild-type (WT, n=74) and EpoR–/–-rescued male mice (n=58) of C57BL/6 background. All of the animals were normotensive.23 EpoR–/–-rescued mice were generated as previously described.21,22 In those EpoR–/–-rescued mice, EpoR is only expressed in the erythroid-lineage cells because EpoR is expressed under control of an erythroid-specific promoter,21 whereas endogenous expression of EpoR mRNA is detected in most of the nonerythroid tissues in WT mice.21 EpoR–/–-rescued mice are thus characterized by the absence of EpoR in cardiovascular system but with normal hematopoietic functions.21,22
Neovascularization After Hindlimb Ischemia
Animals were anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (8 mg/kg). Hindlimb ischemia was made by left femoral artery ligation, as previously described.6 We measured blood flow ratio at ischemic limb (left)/nonischemic limb (right) using a laser Doppler blood flowmeter (Laser Doppler Imager, Moor Instruments Ltd, Devon, UK). The average blood flow ratio of 2 measurements was calculated on the basis of colored histogram pixels.6 Capillary density was determined in 20 µm-thick frozen sections of the proximal thigh adductor muscles.
Histological Assays
Immunohistochemistry was performed using anti-mouse CD31 (1:100; BD PharMingen), anti-mouse VEGF receptor-2 (VEGFR-2/Flk-1/KDR) (1:100; Santa Cruz), anti-mouse VEGF-A (1:100; Santa Cruz) and tetramethylrhodamine isothiocyanate (TRITC)-labeled lectin (1:100; Sigma) antibodies.22 Slides were viewed with a laser scanning microscope (LSM510 META, Carl Zeiss, Jena, Germany) and the image browser (Carl Zeiss, Jena, Germany) was used to create a pseudo-3D projection from serial Z-sections through the entire thickness.24
Endothelium-Like Cell Assay
Endothelium-like cell assay was performed as previously described.16,19,22 On the day of surgery and day 7, wild-type mice received an intravenous infusion of Cell Tracker CM-DiI (Molecular Probes, Eugene, Ore)-labeled endothelium-like cells (1x106 cells/mouse) isolated from WT or EpoR–/–-rescued mice as previously described.22 Control mice were injected with PBS alone. We injected the cells twice to enhance the detection.
Evaluation of Mobilized EPCs
To examine the role of the Epo/EpoR system in EPC mobilization in response to ischemia, we used fluorescein isothiocyanate (FITC) anti-mouse CD133 (NO. 11-1331, eBioscience, Calif) and phycoerythrin (PE) anti-mouse Flk-1 (VEGFR-2, NO. 12-5821, eBioscience, Calif) antibodies. The number of VEGFR-2+/CD133+ cells in peripheral blood mononuclear cells were examined by fluorescence-activated cell sorter (FACS calibur; Becton Dickinson, San Jose, Calif).16,19,22,25
Enzyme-Linked Immunosorbent Assay for VEGF
Enzyme-linked immunosorbent assay (ELISA) was performed with a mouse-specific VEGF ELISA kit (Quantikine M, R&D Systems, Minneapolis, Minn), following the manufacturer’s protocol. Protein extracted from muscle homogenates with the Tissue Protein Extraction Reagent (T-PER, Pierce) were standardized for total protein content using the BCA Protein Assay kit (Pierce) as previously described.26
Western Blotting
Cell lysates from hindlimb tissue homogenates were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore). Subsequently, the membranes were probed with antibodies to mouse VEGFR-2/Flk-1 (Santa Cruz, Calif), VEGFR-1/Flt-1 (Santa Cruz, Calif), and GAPDH (Santa Cruz, Calif). Signals were visualized by the ECL detection system (Amersham Biosciences, Uppsala, Sweden).22
BM Transplantation
BM transplantation was performed as previously described.18,22 The chimeric rate was more than 95% by FACS analysis.
Skeletal Muscle-Derived Mononuclear Cells From Green Fluorescent Protein-BM Chimeric Mice
Transgenic mice ubiquitously expressing enhanced green fluorescent protein (GFP)27 were used to generate GFP-BM chimeric mice as previously described.18,22 Cells among the ischemic and nonischemic tissues were extracted from the thigh adductor muscles at 2 weeks after the ischemic injury.28 Subsequently, the cells obtained were stained with PE-labeled anti-mouse VEGF receptor (VEGFR)-2 (NO. 12-5821, eBioscience, Calif). Dead cells were stained with propidium iodide (PI).28 Six weeks after the BM transplantation, the chimeric mice were rendered an hindlimb ischemic injury and the number of GFP+ cells in the ischemic tissue was counted by confocal microscopy and FACS analysis.28
Matrigel Implantation Assay
The Matrigel (Becton Dickinson) implantation assay was performed by injecting 200 µL of growth factor-reduced Matrigel containing VEGF (Invitrogen, 100 ng/mL) plus heparin (20 U/mL) into the abdominal subcutaneous tissue of each mouse.29 The gels were removed on day 14 and the sections of the gels were stained with FITC-labeled anti-mouse CD31 (1:100; BD PharMingen) and Cy3-labeled 
-smooth muscle actin (1:400; C6198, 1A4, Sigma).29
Aortic Ring Assay for Angiogenesis
The aortic ring assay was performed as previously described.30 Briefly, the descending thoracic aorta was isolated and 1-mm long aortic rings were embedded in growth factor-reduced Matrigel supplemented with 20 U/mL heparin. The aortic rings were then cultured in endothelial basal medium (EBM-2, Cambrex Bioscience) supplemented with or without 10 IU/mL human recombinant Epo (Kirin Brewery Co, Tokyo, Japan) and/or 50 ng/mL human recombinant VEGF (Invitrogen) at 37°C.
Statistical Analysis
Quantitative results are expressed as means±SD. Statistical analyses were performed with StatView (StatView 5.0, SAS Institute Inc, Cary, NC). Comparisons of parameters among the 3 groups were made by one-way ANOVA, and comparisons of parameters between the 2 genotypes under different conditions were made by 2-way ANOVA, followed by Bonferroni post-hoc test. A value of P<0.05 was considered to be statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Angiogenesis After Femoral Artery Ligation
Immediately after the femoral artery ligation, blood flow in ischemic hindlimb was equally decreased in both strains (Figure 1A and 1B). Although blood flow in ischemic hindlimb was recovered in WT mice until day 14, the recovery was significantly impaired in EpoR–/–-rescued mice (Figure 1A and 1B). In addition, histological analysis revealed that the capillary density in ischemic limb was significantly increased in WT mice whereas no such increase was noted in EpoR–/–-rescued mice (Figure 1C and 1D). However, the real-time RT-PCR showed that there was no significant difference in mRNA levels of EpoR between the ischemic and nonischemic limbs in wild-type mice (supplemental Figure I in the online data supplement available at http://circres.ahajournals.org). Furthermore, there were no significant differences in Epo or eNOS levels when evaluated by ELISA in the ischemic and nonischemic tissues in wild-type and EpoR–/–-rescued mice (supplemental Figure II and III in the online data supplement available at http://circres.ahajournals.org).
|
VEGFR-2+/CD133+ Cell and Endothelium-Like Cell Mobilization
The number of VEGFR-2+/CD133+ cells in peripheral blood mononuclear cells was significantly increased after the hindlimb ischemic injury in WT mice but not in EpoR–/–-rescued mice (Figure 2A). Endothelium-like cell assay with CM-DiI-labeling demonstrated that endothelium-like cell migration and homing to the endothelium of the ischemic tissue was significantly impaired in EpoR–/–- rescued mice compared with WT mice (Figure 2B and 2C). Furthermore, injection of endothelium-like cells from WT mice, but not those from EpoR–/–-rescued mice, improved blood flow recovery after the hindlimb ischemia (Figure 2D).
|
VEGF Concentrations and Recruitment of BM-Derived Cells
Immunostaining revealed that VEGF expression was enhanced in the ischemic tissue of WT mice compared with EpoR–/–-rescued mice (Figure 3A). VEGF concentrations in ischemic tissue was also significantly higher in WT mice than in EpoR–/–-rescued mice (Figure 3B), indicating the crucial role of vascular Epo/EpoR system in ischemia-induced VEGF secretion.
|
To completely exclude the effect of Epo/EpoR system on BM-derived cells, we performed BM transplantation, where BM cells from WT and EpoR–/–-rescued mice were reconstituted with those from GFP-transgenic mice. Six weeks after the BM transplantation, confocal microscopy revealed that not only ischemic muscle but also migrated BM-derived cells (GFP+ cells) expressed VEGF (Figure 3C). The VEGF expression was more enhanced in the skeletal muscle close to GFP+ cells (Figure 3C, arrows).
In addition, the number of GFP+ cells was significantly increased in ischemic tissue, especially around the vessels in WT mice, but not in EpoR–/–-rescued mice (Figure 4A). Similarly, the number of GFP+ cells detected by FACS analysis was significantly increased in ischemic tissue in WT mice compared with EpoR–/–-rescued mice (Figure 4B). Furthermore, ischemia significantly enhanced the expression of VEGFR-2 (Flk-1) in skeletal muscle in WT mice, but not in EpoR–/–-rescued mice, although there was no significant change in the expression of VEGFR-1 (Flt-1, Figure 4C).
|
Furthermore, to evaluate the contribution of BM-derived cells to postischemic angiogenesis, we made the following 4 groups of chimeric mice: (1) WT mice transplanted with BM cells from WT mice; (2) WT mice transplanted with BM cells from EpoR–/–-rescued mice; (3) EpoR–/–-rescued mice transplanted with BM cells from WT mice; and (4) EpoR–/–-rescued mice transplanted with BM cells from EpoR–/–-rescued mice (Figure 5A). Two weeks after the hindlimb ischemia, the blood flow ratio was higher in WT recipients, and reduced in of EpoR–/–-rescued recipients, regardless of the source of BM (Figure 5A and 5B).
|
WT, WT mice reconstituted with WT-BM; EpoR–/–-rescued
Roles of Vascular Epo/EpoR System in Response to VEGF
To further investigate the role of EpoR in peripheral microvessels, we subcutaneously injected Matrigel with or without VEGF (100 ng/mL) in WT and EpoR–/–-rescued mice. On day 14 after the injection, we examined VEGF-induced growth of blood vessels (Figure 6A). The number of the vessels was significantly increased in the Matrigel in response to VEGF in both strains, however, the increase was significantly impaired in EpoR–/–-rescued mice compared with WT mice (Figure 6B). Furthermore, in the aortic ring assay, Epo (10 IU/mL) or VEGF (50 ng/mL) increased the number of microvessels sprouting from aortic rings in WT mice compared with EpoR–/–-rescued mice (Figure 7). Epo, when added to VEGF, further enhanced the microvessel sprouting in WT mice but not in EpoR–/–-rescued mice (Figure 7).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The novel finding of the present study is that vascular Epo/EpoR system plays an important role in ischemia-induced angiogenesis in mice in vivo. To the best of our knowledge, this is the first study that demonstrates the important roles of vascular EpoR system, including induction of postischemic angiogenesis, secretion of VEGF from ischemic muscle and BM-derived cells, enhancement of VEGFR-2 in ischemic tissue, and recruitment of BM-derived cells to ischemic tissue.
Epo and Angiogenesis in Local Ischemia
Tissue ischemia/hypoxia activates HIF-1, which activates Epo and enhances VEGF expression, mobilizes EPCs, and finally contributes to neovascularization.5,7,18 Administration of exogenous Epo also augments the proliferation of stem/progenitor cells in BM and induces mobilization and proliferation of EPCs.16,31 Although the enhancing effect of Epo has long been thought to be limited to the kidney, HIF-1-induced production of Epo is also detected in hypoxic retina.32 However, in the present study, we were unable to detect Epo mRNA in ischemic muscle in WT or EpoR–/–-rescued mice, and plasma levels of Epo were comparable after femoral artery ligation between the two genotypes (data not shown). By contrast, both VEGF concentrations and recruitment of BM-derived cells in ischemic muscle were significantly enhanced in WT mice, but were significantly impaired in EpoR–/–-rescued mice. These results suggest that EpoR may be important for VEGF secretion, EPC mobilization, and angiogenesis in ischemic tissue as well as Epo in peripheral vasculature.
EpoR and Angiogenesis in Local Ischemia
Although systemic administration of Epo is known to cause angiogenesis, the role of local EpoR remains to be elucidated. However, as demonstrated in the present study (supplemental Figure I and II), hindlimb ischemia in WT mice did not modify Epo/EpoR expressions, probably because both Epo and hypoxia are required to upregulate EpoR.15 Therefore, we used EpoR–/–-rescued mice to evaluate the role of EpoR in hindlimb ischemia. As demonstrated in the present study, vascular EpoR plays a key role to induce angiogenesis in response to ischemia. The VEGF/VEGFR-2 system is also important to mobilize EPCs from BM as an endogenous chemotactic system for BM-derived proangiogenic CXCR4+ cells.33,34 The present study demonstrates that vascular EpoR is important to upregulate the VEGF/VEGFR-2 system and to mobilize EPCs in local ischemic tissue. Even after BM transplantation, the lack of EpoR in peripheral vasculature resulted in the incomplete improvement of VEGF secretion and angiogenesis, probably because some signals through EpoR were required to induce VEGF/VEGFR-2 system in ischemic limb. The VEGF-supplemented Matrigel implantation and aortic ring assays (Figure 6 and 7
) also indicate that the lack of EpoR in vasculature is responsible for the impaired angiogenesis even in the presence of VEGF, where the responses to Epo also were significantly impaired. Therefore, we consider that EpoR is, at least partially, contributed to VEGF-induced angiogenesis in the present study. These results indicate that local vascular EpoR, as well as Epo, promotes postischemic angiogenesis by enhancing VEGF secretion from ischemic muscle, EPC mobilization, and recruitment of BM-derived proangiogenic cells to the ischemic tissue. The impaired angiogenesis in EpoR–/–-rescued mice is not only because of the reduced VEGF secretion and the impaired recruitment of proangiogenic BM-derived cells, but also because of the reduced responsiveness of blood vessels to VEGF in the absence of EpoR.
Clinical Implications
It has been recently demonstrated that administration of recombinant human Epo ameliorates congestive heart failure in humans35 and protects myocardium from ischemia/reperfusion injury in mice.35,36 We also have recently demonstrated that the number of apoptotic myocytes is significantly increased after myocardial ischemia/reperfusion injury in EpoR–/–-rescued mice23 and that plasma concentrations of Epo are closely related with cardiac function in patients with acute myocardial infarction.23,37 In the present study, we were able to demonstrate that local vascular EpoR, in addition to Epo, plays an important role to promote ischemia-induced angiogenesis. Therefore, modulation of vascular EpoR system could be a new therapeutic strategy for the treatment of ischemic cardiovascular diseases, including PAD, although further clinical investigations are needed.
|
Acknowledgments |
|---|
We thank Kirin Brewery Co, Ltd, for providing human recombinant Epo, and Drs M. Yamamoto and N. Suzuki at Tsukuba University for providing EpoR–/–-rescued mice and Dr N. Minegishi for valuable comments.
Sources of Funding
This study was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (16209027, 16659192, 18659218), the Japanese Ministry of Health, Labor, and Welfare, Tokyo, Japan, and the Japan Foundation of Cardiovascular Research, Tokyo, Japan.
Disclosures
None.
|
Footnotes |
|---|
Original received August 2, 2006; revision received December 19, 2006; accepted January 25, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the Am Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the Am Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006; 47: 1239–1312.
2. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996; 348: 370–374.[CrossRef][Medline] [Order article via Infotrieve]
3. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998; 98: 2800–2804.
4. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002; 360: 427–435.[CrossRef][Medline] [Order article via Infotrieve]
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92: 5510–5514.
6. Lee CW, Stabile E, Kinnaird T, Shou M, Devaney JM, Epstein SE, Burnett MS. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J Am Coll Cardiol. 2004; 43: 474–482.
7. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992; 12: 5447–5454.
8. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16: 4604–4613.[Abstract]
9. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.[CrossRef][Medline] [Order article via Infotrieve]
10. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation. 2004; 109: 2692–2697.
11. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006; 124: 175–189.[CrossRef][Medline] [Order article via Infotrieve]
12. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992; 72: 449–489.
13. Haller H, Christel C, Dannenberg L, Thiele P, Lindschau C, Luft FC. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996; 50: 481–488.[Medline] [Order article via Infotrieve]
14. Alvarez Arroyo MV, Castilla MA, Gonzalez Pacheco FR, Tan D, Riesco A, Casado S, Caramelo C. Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation. J Am Soc Nephrol. 1998; 9: 1998–2004.[Abstract]
15. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004; 104: 2073–2080.
16. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003; 102: 1340–1346.
17. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood. 2004; 103: 921–926.
18. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221–228.
19. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 9: 1370–1376.[CrossRef][Medline] [Order article via Infotrieve]
20. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994; 91: 3974–3978.
21. Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002; 100: 2279–2288.
22. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, Ono M, Watanabe J, Shirato K, Ishii N, Sugamura K, Shimokawa H. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation. 2006; 113: 1442–1450.
23. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Satoh K, Ito K, Karibe A, Shirato K, Minegishi N, Shimokawa H. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res. 2006; 71: 466–477.
24. O’Neill TJt, Wamhoff BR, Owens GK, Skalak TC. Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. Circ Res. 2005; 97: 1027–1035.
25. Kania G, Corbeil D, Fuchs J, Tarasov KV, Blyszczuk P, Huttner WB, Boheler KR, Wobus AM. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells. 2005; 23: 791–804.[CrossRef][Medline] [Order article via Infotrieve]
26. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858–864.[CrossRef][Medline] [Order article via Infotrieve]
27. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. ‘Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997; 407: 313–319.[CrossRef][Medline] [Order article via Infotrieve]
28. Tamaki T, Uchiyama Y, Okada Y, Ishikawa T, Sato M, Akatsuka A, Asahara T. Functional recovery of damaged skeletal muscle through synchronized vasculogenesis, myogenesis, and neurogenesis by muscle-derived stem cells. Circulation. 2005; 112: 2857–2866.
29. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, Sonoda H, Sato Y. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004; 114: 898–907.[CrossRef][Medline] [Order article via Infotrieve]
30. Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, Noel A, Foidart JM. Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis. 2001; 4: 133–142.[CrossRef][Medline] [Order article via Infotrieve]
31. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005; 68: 299–306.
32. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Reme CE. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002; 8: 718–724.[CrossRef][Medline] [Order article via Infotrieve]
33. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J. 1999; 18: 3964–3972.[CrossRef][Medline] [Order article via Infotrieve]
34. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med. 2006; 12: 557–567.[CrossRef][Medline] [Order article via Infotrieve]
35. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000; 35: 1737–1744.
36. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003; 100: 4802–4806.
37. Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, Kunii H, Yamao H, Komatsu N, Yui M, Tada H, Sakuma M, Watanabe J, Ichihara T, Shirato K. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 45: 1406–1412.
Related Article:
Circ. Res. 2007 100: 599-601.
This article has been cited by other articles:
 |
|
 |
|
  T. E. Perry, M. Song, D. J. Despres, S. M. Kim, H. San, Z.-X. Yu, N. Raghavachari, J. Schnermann, R. O. Cannon III, and D. Orlic Bone marrow-derived cells do not repair endothelium in a mouse model of chronic endothelial cell dysfunction Cardiovasc Res, November 1, 2009; 84(2): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schroder, A. Kohnen, A. Aicher, E. A. Liehn, T. Buchse, S. Stein, C. Weber, S. Dimmeler, and R. P. Brandes NADPH Oxidase Nox2 Is Required for Hypoxia-Induced Mobilization of Endothelial Progenitor Cells Circ. Res., September 11, 2009; 105(6): 537 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rundqvist, E. Rullman, C. J. Sundberg, H. Fischer, K. Eisleitner, M. Stahlberg, P. Sundblad, E. Jansson, and T. Gustafsson Activation of the erythropoietin receptor in human skeletal muscle Eur. J. Endocrinol., September 1, 2009; 161(3): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-H. Huang, Y.-H. Chen, C.-H. Wang, J.-S. Chen, H.-Y. Tsai, F.-Y. Lin, W.-Y. Lo, T.-C. Wu, M. Sata, J.-W. Chen, et al. Matrix Metalloproteinase-9 Is Essential for Ischemia-Induced Neovascularization by Modulating Bone Marrow-Derived Endothelial Progenitor Cells Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, H. Okada, G. Takemura, M. Esaki, H. Kobayashi, H. Kanamori, I. Kawamura, R. Maruyama, T. Fujiwara, H. Fujiwara, et al. Sustained Release of Erythropoietin Using Biodegradable Gelatin Hydrogel Microspheres Persistently Improves Lower Leg Ischemia J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2378 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brunner, J. Winogradow, B. C. Huber, M.-M. Zaruba, R. Fischer, R. David, G. Assmann, N. Herbach, R. Wanke, J. Mueller-Hoecker, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis FASEB J, February 1, 2009; 23(2): 351 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. T. Hare, A. K. Y. Tsui, A. T. McLaren, T. E. Ragoonanan, J. Yu, and C. D. Mazer Anemia and Cerebral Outcomes: Many Questions, Fewer Answers Anesth. Analg., October 1, 2008; 107(4): 1356 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, S. Minatoguchi, S. Yasuda, N. Bao, I. Kawamura, M. Iwasa, T. Yamaki, S. Sumi, Y. Misao, H. Ushikoshi, et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair Cardiovasc Res, September 1, 2008; 79(4): 611 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shimokawa Bone Marrow-Derived Matrix Metalloproteinase-14: A Novel Target for Plaque Stability Circulation, February 19, 2008; 117(7): 863 - 865. [Full Text] [PDF]
|
|
|
|
|
|
K. Satoh and B. C. Berk Circulating smooth muscle progenitor cells: novel players in plaque stability Cardiovasc Res, February 1, 2008; 77(3): 445 - 447. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Menne, J.-K. Park, N. Shushakova, M. Mengel, M. Meier, and D. Fliser The Continuous Erythropoietin Receptor Activator Affects Different Pathways of Diabetic Renal Injury J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2046 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stamm ICVTS on-line discussion B Don't give up, yet! Interactive CardioVascular and Thoracic Surgery, June 1, 2007; 6(3): 297 - 297. [Full Text] [PDF]
|
|
|
|
|
|
P. Madeddu and C. Emanueli Switching on Reparative Angiogenesis: Essential Role of the Vascular Erythropoietin Receptor Circ. Res., March 16, 2007; 100(5): 599 - 601. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||